dromlakhani Targeted Therapies to Treat Ectopic ACTH Syndrome
STEP 1 — Gather Information
Confirm ectopic ACTH secretion: serum ACTH >20 pg/mL with unsuppressible cortisol, low‑dose dexamethasone non‑suppression, and no pituitary lesion on MRI. Perform inferior petrosal sinus sampling if pituitary source uncertain. Obtain cross‑sectional imaging (CT chest/abdomen/pelvis, somatostatin receptor PET/CT or DOTATATE PET) to localize tumor and assess resectability. Review prior medical therapy and comorbidities.
Action: Proceed to Rule In/Rule Out.
STEP 2 — Rule In / Rule Out
Rule In: Elevated ACTH with cortisol excess and no pituitary source confirms ectopic ACTH syndrome.
Rule Out: If ACTH is normal/pituitary lesion identified on MRI or petrosal sampling, consider Cushing’s disease or adrenal etiology and redirect to appropriate pathway.
Action: If ectopic ACTH confirmed, advance to classification; otherwise reconsider diagnosis.
STEP 3 — Classify or Stratify
Stratify by tumor type and resectability:
- Occult or metastatic ectopic ACTH‑secreting tumor (non‑MTC) → consider somatostatin analog.
- Ectopic ACTH from metastatic medullary thyroid carcinoma → consider tyrosine kinase inhibitor.
- Tumor resectable → prioritize surgical referral over medical targeted therapy.
Action: Select appropriate targeted therapy class based on tumor type.
STEP 4 — Decide
For occult/metastatic non‑MTC ectopic ACTH: initiate pasireotide 600–900 µg SC twice daily (or lanreotide/octreotide per labeling).
For metastatic MTC‑driven ectopic ACTH: start vandetanib 300 mg PO daily (or sorafenib 400 mg PO twice daily).
If patient cannot take oral agents or has life‑threatening hypercortisolism, use etomidate infusion as a bridge while arranging definitive therapy.
Action: Initiate the chosen targeted therapy and schedule baseline labs (LFTs, ECG, glucose, cortisol) and follow‑up imaging.
Clinical Guardrails / Mimics / Pitfalls
Monitor pasireotide‑treated patients for hyperglycemia (check fasting glucose q1‑2w), QT prolongation, and cholelithiasis; avoid in patients with uncontrolled diabetes.
Vandetanib/sorafenib require ECG and LFT monitoring; hold for QTc >480 ms or grade ≥3 hepatic toxicity.
Do not rely solely on targeted therapy if the tumor is surgically resectable; surgery remains first‑line when feasible.
Be aware that somatostatin analogs may control cortisol without tumor shrinkage; lack of size does not preclude continued use if biochemical control is achieved.
Avoid delaying definitive surgery or radiotherapy when a curative option exists.
Concrete Clinical Example
A 58‑year‑old woman with metastatic medullary thyroid carcinoma presented with ectopic ACTH‑driven Cushing’s syndrome (ACTH 210 pg/mL, UFC 450 µg/24h) unresponsive to ketoconazole. Vandetanib 300 mg daily was started; after 4 weeks UFC normalized to 45 µg/24h, blood pressure improved, and hyperglycemia resolved. Therapy continued with monthly ECG and LFTs; no dose adjustments needed.
Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., Endocrine Society, 2015, DOI:10.1210/jc.2015-1818